Abstract
The immune system protects organisms from pathogens. The immune cells, in particular T- and B-lymphocytes, develop and acquire effector functions in specialized tissues called the lymphoid organs. The lymphoid organs exhibit lower oxygen tensions than the blood or the atmosphere. Furthermore, inflammatory and tumor environments where lymphocytes execute effector functions also have very low oxygen tensions. These findings led to the hypothesis that lymphocytes may have evolved adaptive mechanisms to function under hypoxic conditions. Cellular responses to hypoxia are triggered by the hypoxia inducible factor-1α (HIF-1α). In this paper we review the development and function of T- and B-lymphocytes in the absence HIF-1a. Our studies suggest that HIF-1α deficiency depresses the function of cytotoxic T-lymphocytes and blocks B-cell development in the bone marrow. B1 lymphocytes of fetal origin, on the other hand, accumulate and may produce auto-antibodies and autoimmunity.
Keywords: hif-, t-lymphocyte, b-lymphocyte, lymphocyte development
Current Pharmaceutical Design
Title: HIF-1α Deficiency Perturbs T and B Cell Functions
Volume: 9 Issue: 23
Author(s): Hidefumi Kojima, Michail V. Sitkovsky and Marilia Cascalho
Affiliation:
Keywords: hif-, t-lymphocyte, b-lymphocyte, lymphocyte development
Abstract: The immune system protects organisms from pathogens. The immune cells, in particular T- and B-lymphocytes, develop and acquire effector functions in specialized tissues called the lymphoid organs. The lymphoid organs exhibit lower oxygen tensions than the blood or the atmosphere. Furthermore, inflammatory and tumor environments where lymphocytes execute effector functions also have very low oxygen tensions. These findings led to the hypothesis that lymphocytes may have evolved adaptive mechanisms to function under hypoxic conditions. Cellular responses to hypoxia are triggered by the hypoxia inducible factor-1α (HIF-1α). In this paper we review the development and function of T- and B-lymphocytes in the absence HIF-1a. Our studies suggest that HIF-1α deficiency depresses the function of cytotoxic T-lymphocytes and blocks B-cell development in the bone marrow. B1 lymphocytes of fetal origin, on the other hand, accumulate and may produce auto-antibodies and autoimmunity.
Export Options
About this article
Cite this article as:
Kojima Hidefumi, Sitkovsky V. Michail and Cascalho Marilia, HIF-1α Deficiency Perturbs T and B Cell Functions, Current Pharmaceutical Design 2003; 9 (23) . https://dx.doi.org/10.2174/1381612033454388
DOI https://dx.doi.org/10.2174/1381612033454388 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Survey of Recent Literature Related to the Biologically Active 4(3H)-Quinazolinones Containing Fused Heterocycles
Current Medicinal Chemistry Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Current Pharmaceutical Design Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Current Cancer Drug Targets Benzophenone Sulfonamide Derivatives as Interacting Partners and Inhibitors of Human P-glycoprotein
Anti-Cancer Agents in Medicinal Chemistry ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Lymphatics and Inflammation
Current Medicinal Chemistry The Role of Tumor Suppressor DLC-1: Far From Clear
Anti-Cancer Agents in Medicinal Chemistry Metastatic Breast Cancer, Organotropism and Therapeutics: A Review
Current Cancer Drug Targets Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles
Anti-Cancer Agents in Medicinal Chemistry Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine